Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone (RCP) for Patients With Newly Diagnosed Multiple Myeloma

NCT00540644 is registered in ClinicalTrials.gov with Attaya Suvannasankha as lead sponsor.

NCT NCT00540644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00540644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone (RCP) for Patients With Newly Diagnosed Multiple Myeloma
Lead sponsor
Attaya Suvannasankha
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2007
Completion date
August 31, 2014
Enrollment
70 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma